Login to Your Account

Pharma: Other News To Note

Thursday, April 5, 2012
• Codexis Inc., of Redwood City, Calif., is using its CodeEvolver directed evolution technology in a collaboration with Merck & Co. Inc., of Whitehouse Station, N.J., to develop a highly efficient, cost-effective, enzyme-based production method for an intermediate used in boceprevir, the active ingredient in Merck's hepatitis C drug Victrelis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription